RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07662395, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. For subjects with adenocarcinoma, non-smokers, or squamous cell carcinoma with mixed adenocarcinoma components, absence of sensitizing EGFR mutations (e.g., exon 19 deletion, exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I) or ALK gene rearrangements must be confirmed by tumor tissue, cytology, or blood samples prior to enrollment.

    Inclusion criterion 6

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

    Inclusion criterion 3

  4. Pregnant or breastfeeding women.

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07662395, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntary written informed consent (ICF) signed prior to screening.
  • Age ≥18 years, male or female.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Expected survival ≥3 months.
  • Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) that is not amenable to complete surgical resection and is not suitable for definitive concurrent or sequential chemoradiotherapy, according to the 9th edition of the TNM staging system by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC).
  • For subjects with adenocarcinoma, non-smokers, or squamous cell carcinoma with mixed adenocarcinoma components, absence of sensitizing EGFR mutations (e.g., exon 19 deletion, exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I) or ALK gene rearrangements must be confirmed by tumor tissue, cytology, or blood samples prior to enrollment.
  • Availability of tumor tissue samples for PD-L1 testing.
  • No prior systemic anticancer therapy for the study disease.
  • At least one measurable lesion (excluding brain lesions) per RECIST v1.1. 10 Adequate organ function.

Exclusion Criteria:

  • Known ROS1 fusion-positive, BRAF V600E mutation, or other driver mutations for which guideline-recommended first-line targeted therapies are available.
  • Prior thoracic radiotherapy.
  • Symptomatic central nervous system metastases.
  • Imaging evidence during screening showing tumor invasion of major blood vessels, invasion of critical surrounding organs, or risk of tracheoesophageal fistula or esophagopleural fistula as assessed by the investigator.
  • History of hypertensive crisis or hypertensive encephalopathy, or uncontrolled hypertension despite medication.
  • Active autoimmune disease or a history of autoimmune disease with a risk of recurrence.
  • Bleeding tendency, high bleeding risk, or coagulation disorders.
  • Other malignancies.
  • Active serious infection prior to first dose, including active infection, active tuberculosis, HIV positivity, active hepatitis B or C, or known active syphilis.
  • Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  • History of non-infectious pneumonia requiring systemic corticosteroid therapy or current interstitial lung disease.
  • Prior allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  • Known allergy to any component of the investigational drug(s), or history of severe hypersensitivity reaction to any monoclonal antibody.
  • Participation in another clinical trial, except for follow-up in observational (non-interventional) studies or follow-up phases of interventional studies.
  • Pregnant or breastfeeding women.
  • Known alcohol or drug abuse, psychiatric disorders, or history of illicit drug use.
  • Any other condition deemed unsuitable for enrollment by the investigator.

Quoted from ClinicalTrials.gov, NCT07662395, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07662395, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07662395